The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial. - Wikidata - wikimedia - TriplyDB

The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.

The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.

http://www.wikidata.org/entity/Q50547059

about

A Multi-scale Computational Platform to Mechanistically Assess the Effect of Genetic Variation on Drug Responses in Human Erythrocyte Metabolism Roles of functional catechol-O-methyltransferase genotypes in Chinese patients with Parkinson's disease.COMT Val158Met Polymorphism Modulates Huntington's Disease Progression.The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson's disease with a sexual dimorphism.Putative cortical dopamine levels affect cortical recruitment during planning.Pharmacogenetics of Parkinson's disease - through mechanisms of drug actions.Pharmacological treatment and the prospect of pharmacogenetics in Parkinson's disease.Pharmacogenomics in neurology: current state and future steps.Anti-Parkinson's disease drugs and pharmacogenetic considerations.Parkinson's disease pharmacogenomics: new findings and perspectives.Pharmacogenetics of drug response in Parkinson's disease.Pharmacogenetic considerations in the treatment of Parkinson's disease.How close are we to individualized medicine for Parkinson's disease?Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study.A neurological perspective on the enhancement debate: Lessons learned from Parkinson's disease.Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.A systematic review and integrative approach to decode the common molecular link between levodopa response and Parkinson's disease Association Between Catechol-O-Methyltransferase (COMT) Gene Polymorphisms, Parkinson's Disease, and Levodopa Efficacy.Association between maternal COMT gene polymorphisms and fetal neural tube defects risk in a Chinese population.Genetics and Treatment Response in Parkinson's Disease: An Update on Pharmacogenetic Studies.Adverse effects produced by different drugs used in the treatment of Parkinson's disease: A mixed treatment comparison.Levodopa-entacapone-carbidopa intestinal gel in Parkinson's disease: A randomized crossover study.

P2860

Q28553224-F1498872-3D40-4A93-A9E4-5426A8807BAA Q33604514-8DC8C719-AB38-441F-A66D-B9D98F724219 Q36140827-BFA6440D-B827-4EE3-9429-4BC982CC865A Q36822049-F0F7D053-0E67-4B8E-BA24-FF2FDFD2B02E Q37254819-1689F689-9AE5-4B51-87E4-83F7C6CA3D32 Q37583417-9C61AC40-27DE-4E48-B1A5-5A5B84A543F2 Q37957393-906B51CB-8550-4A89-B7FA-52A2825E26C9 Q37967607-23490B1A-DC40-433D-9C66-AAB45F9AD968 Q38097097-4CFEF40C-8B49-408F-BF7F-A23D1D692A91 Q38241678-71C70F69-5175-40DB-888A-41D379594E2E Q38250117-B9C34B89-4F3E-4BA0-A528-8D419644891B Q38364825-09A004F5-1001-4B3B-98D2-4B67253323DE Q38814888-F7D39196-EBAA-45C6-9259-EC02FFEF7BAE Q38865983-7BBBEA0C-563C-4B5A-B17E-2CBA7FAE29C5 Q38948788-17944924-323F-481E-A033-210E76EE7D2A Q41168222-276B1636-1E6C-401D-A796-71476F09938C Q41711967-1A030E2A-33F4-4D06-A89B-A91BFBFDF1BD Q43662733-50385EE5-9F8D-4503-BAFC-EF7404D48622 Q44990623-2FD90990-6191-480D-B811-0DB3E117C6F2 Q47648607-EEFFBE3B-1219-4B2C-85D0-A42DFD23C07B Q48129862-4F49974B-FD40-4139-9052-4FFDAD58690C Q48721847-B2249278-8376-42B9-BCC9-CA35AAA0BA46

P2860

The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.

http://www.wikidata.org/entity/Q50547059

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

The COMT Val158Met polymorphis ...... ized crossover clinical trial.

@en

The COMT Val158Met polymorphis ...... ized crossover clinical trial.

@nl

type

label

The COMT Val158Met polymorphis ...... ized crossover clinical trial.

@en

The COMT Val158Met polymorphis ...... ized crossover clinical trial.

@nl

prefLabel

The COMT Val158Met polymorphis ...... ized crossover clinical trial.

@en

The COMT Val158Met polymorphis ...... ized crossover clinical trial.

@nl

P1433

Q50547059-0E0DE657-9847-4A01-B5CF-F8596C45D4F5

P1476

Q50547059-E690490B-2BCC-4781-8E8B-12CEC667CEB4

P2093

Q50547059-196BEFAC-D6C7-4F78-B776-649596DD53D1

Q50547059-19D7ABB3-1E9D-4436-83AC-C39876A11083

Q50547059-1ED0C7F5-319A-4D7D-B390-37B2A9FAC714

Q50547059-4E0E8A93-756C-4004-AE80-BD497844E60C

Q50547059-6EB39AF7-3357-4C4A-AB7C-8F5E1B6508FB

Q50547059-6FADBC69-56EA-4FCF-95A8-C6E8D68738BC

Q50547059-87774342-67B9-41C4-8697-9043D03CB881

Q50547059-9F38AEC9-4603-49DE-B0B8-9E9AEE686792

Q50547059-A26ACC9F-D7BC-4705-BE41-95E6C38E0C45

Q50547059-DE7745B6-6D11-4E03-8645-5F54F14F01C6

P2860

Q50547059-04FC261E-095D-4060-BF9A-C21BDDBBCEE6

Q50547059-0749EF34-8AAF-4E71-82E6-B7ED9E009126

Q50547059-48171AA1-C7AE-48BC-A5C4-C45BD2D199C2

Q50547059-63C5008E-ED43-4E74-8730-C692362348BF

Q50547059-786A5826-6B23-456C-B10B-E93522503879

Q50547059-8F2C512E-92B5-4C0F-9845-5D48F8182620

Q50547059-918C1F9D-80D1-4F6B-B80F-F05DD77044BF

Q50547059-98049A7B-C88B-41FC-92F0-2EFB018AAE39

Q50547059-DB15E450-0E40-43AF-AB00-3FAD1DCD6337

Q50547059-E82796E6-FCB4-4077-8D5A-DA22F6CB9B77

P304

Q50547059-DC2B664D-EBF0-496D-B151-E9AD032AF715

P31

Q50547059-A8B5A0AD-CAE7-4328-B132-3F2D6A2134F9

P356

Q50547059-33F36709-3F16-45B2-BEE7-193876DFCFAA

P433

Q50547059-292FC249-741F-44B8-AD30-A28AC831E13F

P478

Q50547059-ABEDFB04-AB38-44D6-B9E7-D2DC383CFE09

P50

Q50547059-00899166-7111-4A0E-8A97-85DA2CCB9A29

Q50547059-3A3CE630-B500-4C1B-95C0-B9C543BDBF05

Q50547059-3BD1E18B-D54B-49EC-8E05-31046DB7660D

Q50547059-91DFC63B-E863-4AAB-9405-2B09C00ACEEF

P577

Q50547059-829FB952-41F6-4796-8CC1-DA0D4E83E633

P698

Q50547059-CD1C84CF-6B1C-4346-ACEE-56E50A7F5295

P921

Q50547059-9BF7E9E4-4C81-4A30-85A6-1997478894E4

P356

P1433

Annals of Neurology

P1476

The COMT Val158Met polymorphis ...... ized crossover clinical trial.

@en

P2093

Agnès Bellanger

http://www.w3.org/2001/XMLSchema#string

Andreas Hartmann

http://www.w3.org/2001/XMLSchema#string

Anne-Marie Bonnet

http://www.w3.org/2001/XMLSchema#string

Cécilia Bonnet

http://www.w3.org/2001/XMLSchema#string

Cédric Vrignaud

http://www.w3.org/2001/XMLSchema#string

Emmanuel Roze

http://www.w3.org/2001/XMLSchema#string

Fanny Charbonnier-Beaupel

http://www.w3.org/2001/XMLSchema#string

Gayané Meliksetyan

http://www.w3.org/2001/XMLSchema#string

Jean Costentin

http://www.w3.org/2001/XMLSchema#string

Lucette Lacomblez

http://www.w3.org/2001/XMLSchema#string

P2860

Levodopa-related wearing-off in Parkinson's disease: identification and management

New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease.

Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA.

Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease.

Determination of catechol-O-methyltransferase activity in erythrocytes by high performance liquid chromatography with electrochemical detection.

Medical management of levodopa-associated motor complications in patients with Parkinson's disease.

Variations in catechol-O-methyltransferase activity in inbred strains of rats.

COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease.

Association between catechol-O-methyltransferase gene polymorphisms and wearing-off and dyskinesia in Parkinson's disease.

Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease.

P304

111-118

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ANA.22155

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Sébastien Hulot

Jean-Christophe Corvol

Marie Vidailhet

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21280081

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease